First Patient Enrolled in HIV Combination Maintenance Therapy Study

July 29, 2022

Built on a long-standing partnership with TaiMed Biologics, Inc., (TaiMed), Westat and TaiMed have announced the first patient has been enrolled in the new TMB-a21 study.

TMB-a21 is a Phase 1b/2a study involving HIV-1 infected patients who are virally suppressed. The investigational products, TMB-365 and TMB-380, are monoclonal antibodies administered together via intravenous infusion. The study is designed to evaluate the safety, pharmacokinetics, and efficacy of this experimental combination at different doses and dosing intervals. 

Westat’s Senior Project  Director, Susan Denton, commented, “Westat is honored to work with TaiMed on this groundbreaking HIV research. We’ve worked with TaiMed for more than ten years and continue to focus our efforts on improving the health of people infected with HIV-1.”